Synlogic has been granted a patent for genetically programmed microorganisms, like bacteria, for modulating and treating diseases. The patent includes a method for producing a pharmaceutical composition using genetically-engineered non-pathogenic bacteria to metabolize phenylalanine. The bacteria are grown, isolated, and suspended in a carrier for medical use. GlobalData’s report on Synlogic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Synlogic Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Synlogic, Peptide pharmacophores was a key innovation area identified from patents. Synlogic's grant share as of January 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.

Genetically engineered bacteria for treating phenylketonuria

Source: United States Patent and Trademark Office (USPTO). Credit: Synlogic Inc

A recently granted patent (Publication Number: US11883439B2) discloses a method for producing a pharmaceutically acceptable composition using a genetically-engineered non-pathogenic bacterium designed to metabolize phenylalanine. The bacterium is modified to include heterologous genes encoding a phenylalanine transporter and a polypeptide involved in phenylalanine metabolism, both controlled by inducible promoters not naturally associated with these functions. The method involves growing the bacterium under non-inducing conditions, isolating the bacteria, and suspending them in a carrier for pharmaceutical use.

The patent claims further detail the use of specific promoters for gene expression control, the location of the heterologous genes on either the bacterium's chromosome or a plasmid, and the selection of probiotic bacteria like Escherichia coli strain Nissle for this application. Additionally, the method includes the design of an auxotrophic bacterium that requires specific nutrients present in the human gut for complementation, enhancing its potential therapeutic benefits. The patent highlights the potential applications of this technology in various environments, including the gut microbiome and tumor microenvironments, under specific environmental conditions like low-oxygen or anaerobic settings.

To know more about GlobalData’s detailed insights on Synlogic, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies